Boundless Bio, Inc. Common Stock

BOLDNASDAQUSD
2.60 USD
1.20 (85.71%)AT CLOSE (11:59 AM EDT)
2.68
0.08 (3.08%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
2.68
0.08 (3.08%)
🔴Market: CLOSED

Shares of Boundless Bio, Inc. Common Stock (BOLD) are trading at $2.50. BOLD shows a split signal: technical indicators suggest "Strong Buy" while underlying fundamentals indicate "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation metrics suggest BOLD is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Jun 23, 2026.

Open?$2.40
High?$2.75
Low?$2.25
Prev. Close?$1.40
Volume?65.5M
Avg. Volume?113.4K
VWAP?$2.48
Rel. Volume?577.51x
Bid / Ask
Bid?$1.75 × 3.4K
Ask?$2.65 × 100
Spread?$0.90
Midpoint?$2.20
Valuation & Ratios
Market Cap?31.4M
Shares Out?22.5M
Float?14.0M
Float %?62.8%
P/E Ratio?N/A
P/B Ratio?0.36
EPS?-$2.49
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
Employees
28
Market Cap
32.1M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2024-03-28
Address
10955 ALEXANDRIA WAY
SAN DIEGO, CA 92121
Phone: (858) 766-9912
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+2/3)
Medium-Term (Wave)? Bullish(+3/3)
Short-Term (Ripple)? Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
77
Short Sent.?
80
Piotroski F-Score?0/9Weak
Altman Z-Score?-3.06Distress
Confidence?40%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?0.04%Low
Short Interest?6.1K
Days to Cover?1.0
Free Float14.0M
Avg Daily Volume78.9K
Settlement Date2026-05-29
Financial Health
Current Ratio?9.87Strong
Quick Ratio?9.87Strong
Cash Ratio?1.82Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A
P/B?
Peers
100
S&P
97
0.36CHEAP
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
S&P
97
-0.2CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
3
-64.8%WEAK
ROA?
S&P
3
-39.7%WEAK
Cash Flow & Enterprise
FCF?$-47598000
Enterprise Value?$14.0M
Fundamentals ratios updated end of day